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Background: Both thyroid stimulating hormone (TSH) and thyroid stimulating antibody (TSAb) negative Graves’s
disease (GD) is extremely rare. Here we present such a patient.
Case presentation: The patient was a 76-year-old woman who was diagnosed as having schizophrenia forty years
ago. She did not show characteristic symptoms for hyperthyroidism, such as swelling of thyroid, exophthalmos,
tachycardia and tremor, however, she showed only psychomotor agitation. Serum free triiodothyronine and free
thyroxine levels were elevated and TSH level was suppressed, suggesting the existence of hyperthyroidism.
However, both the first generation TSH receptor autoantibody (TRAb1) and the thyroid stimulating autoantibody
(TSAb) were negative. Slightly increased blood flow and swelling was detected by thyroid echography. Thyroid
scintigraphy demonstrated diffuse and remarkably elevated uptake of 123I uptake. Finally, we diagnosed her as
having GD. She was treated by using methimazole, and hyperthyroidism and her psychiatric symptoms were
promptly ameliorated.
Discussion: We experienced a patient with GD who did not show characteristic symptoms except for psychiatric
symptoms, and also showed negativity for both TRAb1 and TSAb. Thyroid autoantibody-negative GD is extremely
rare. Thyroid scintigraphy was useful to diagnose such a patient.
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Graves’ disease (GD) is induced by autoimmunity for the
thyroid gland, and thyroid stimulating autoantibodies
may be the main pathological cause of GD. We usually
measure thyroid stimulating hormone (TSH) receptor
autoantibodies for diagnosis for GD in medical practices.
In fact, TSH receptor autoantibodies are detectable in
over 90% of patients with GD [1].
Here we present a patient with GD showing the ab-
sence of characteristic symptoms and negativity for both
the first generation TSH receptor autoantibody (TRAb1)
and thyroid stimulating antibody (TSAb).* Correspondence: dyanai@hospk.ncgm.go.jp
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A 76–year-old woman was admitted to the Department
of Psychiatry in our hospital because she denied medica-
tions and suffered from irritability and delusion. She had
no complaints of somatic symptoms. Her thyroid func-
tion was normal at least four months before the admis-
sion, however, laboratory data on the admission revealed
hyperthyroidism. She was pointed out to have thyroid
disease thirty years ago, however, she was not diagnosed
definitively at that time, and also did not take any medi-
cine. She had also type 2 diabetes, hypertension, dyslipide-
mia, hyperuricemia and schizophrenia. The members of
her family did not have thyroid disorders. She has been
taking clonazepam (0.5 mg/day), trazodone (50 mg/day),
nitrazepam (5 mg/day), 0.1% aripiprazole (6 ml/day), pro-
pranolol (30 mg/day) and telmisartan (40 mg/day), for theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and














Figure 1 Changes of free triiodothyronine (FT3) and free thyroxine (FT4).
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http://www.thyroidresearchjournal.com/content/5/1/19treatment for hypertension, psychiatric symptoms and
schizophrenia.
Her body temperature was 35.7°C, blood pressure was
158/86 mmHg, and heart rate was 89 per minute and
regular. Her thyroid was not swelled. She did not have
tremor and exophthalmos. The serum TSH level was
suppressed to < 0.03 μIU/mL (normal: 0.54-4.26 μIU/mL),
free triiodothyronine (T3) and free thyroxine (T4) levels
were elevated to 11.70 pg/mL (normal: 2.39-4.06 pg/mL)


































Figure 2 Changes of the first generation TSH receptor autoantibody
(TRAb2) and thyroid stimulating antibody (TSAb). The cutoff points for
cutoff point for TRAb2 is value recommended by Schott M, et al. [10].(Figure 1). Plasma glucose level was 116 mg/dL (normal:
80–112 mg/dL), and HbA1c level was 6.6% (normal: 4.7-
6.2%). Her liver and renal functions were normal, and
leukocyte counts and C-reactive protein (CRP) level were
not elevated.
Her serum levels of TRAb1 (7.7%; the cutoff point:
15%) and TSAb (155%; the cutoff point: 180%) were not
elevated (Figure 2). Serum anti-thyroid peroxidase
(TPO) antibody was elevated to 174 IU/mL (normal:
< 16 IU/mL). At first, we diagnosed her as havingcutoff: 15 %
cutoff: 2.0 IU/L
2/3 2012/4 2012/5 2012/6
cutoff: 180 %
(TRAb1), the second generation TSH receptor autoantibody
TRAb1 and TSAb are values recommended by manufactures. The
Figure 3 Echography of the thyroid glands. Bilateral thyroid glands was slightly swelled.
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drug. Her psychiatric symptoms continued and we re-
evaluated her thyroid function one month later. The
serum TSH level was still suppressed to < 0.03 μIU/mL
(normal: 0.54-4.26 μIU/mL), and free T3 and free T4
levels were further elevated to 15.88 pg/mL and 4.75 ng/dL,
respectively (Figure 1). Thyroid echography showed slight
swelling of the thyroid gland (right lobe: 52.4 mm×
21.8 mm× 16.4 mm, left lobe: 46.6 mm× 18.7 mm×
12.8 mm, isthmus size: 4.3 mm) and slightly increased
blood flow (Figure 3). Thyroid scintigraphy demonstrated
a diffuse and significantly elevated uptake of 123I uptake in
her thyroid gland (Figure 4). Uptake rate 3 and 24 hours
after injection of 123I was 111% and 63%, respectively Her
serum levels of TRAb1 and TSAb were still not elevated
(Figure 2), in spite of elevation of anti-TPO antibodyFigure 4 Scintigraphy of the thyroid glands. Uptake rate 3 and 24 hour(210 IU/mL; normal: < 16 IU/mL). We evaluated second
generation TRAb (TRAb2), and found that her serum
level of TRAb2 was very weakly positive (2.0 IU/mL; the
cutoff point: 1.0 IU/mL). Because results of thyroid echo-
graphy and scintigraphy strongly suggested the develop-
ment of GD, we treated her by using methimazole
(30 mg/day). Her thyroid function was promptly normal-
ized one month later (Figure 1), and her psychiatric symp-
toms also were ameliorated. Further, the values of TRAb1,
TRAb2 and TSAb were also promptly decreased under
each cutoff point (Figure 2).
Discussion
Hyperthyroidism is a condition where the thyroid gland
abnormally produces too much thyroid hormones. The
most common cause is GD [2,3], and which is developeds after injection of 123I was 111% and 63% respectively.
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http://www.thyroidresearchjournal.com/content/5/1/19by the autoimmune stimulation of the thyroid gland [1].
Standardized diagnostic criteria for GD has not been glo-
bally established, and we usually diagnose this disease by
clinical manifestations, laboratory data and imaging stu-
dies [4]. Clinical symptoms and signs include body weight
loss, tremor, irritability, tachycardia, goiter, exophthalmos.
Our patient had no specific somatic symptom of GD. Ad-
renergic hyperactivity induces psychiatric symptoms in
hyperthyroidism, however. GD patients presenting only
delusion like our patient are uncommon [5,6].
Paunkovic analyzed 255 patients diagnosed as having
GD based on clinical manifestations and laboratory find-
ings (free T4 and TSH). They excluded TRAb positive
patients and the rest of the patients who had hyper-
thyroidism were re-tested with thyroid scintigraphy
and serum levels of another TRAb. These results
showed that TRAb were detectable in 98.7% of
patients with GD. They stated TRAb negative GD was
extremely rare, but there were methodological limita-
tions in the assessment of only TRAb for the valid diag-
nosis of GD [7].
Our case showed no evident clinical manifestations ex-
cept for psychomotor agitation which was considered to
be induced by schizophrenia, and also showed negativity
for both TRAb1 and TSAb. We observed a very weak
positivity of TRAb2 before we started treatment. How-
ever, TRAb or TSAb have been reported to emerge in
about 10% of patients with painless thyroiditis [8,9],
therefore, we cannot make a definite differential diagno-
sis between GD and painless thyroiditis even if one of the
thyroid autoantibodies is very weakly positive. The recom-
mended cut-off value of TRAb2 used to be 2.0 IU/L and
the sensitivity is 93.9% with 100% specificity [10]. It may
be evident that the autoimmune stimulation of the thyroid
gland is the cause of hyperthyroidism in our patient be-
cause serum levels of thyroid autoantibodies (TRAb1,
TRAb2 and TSAb) were significantly decreased after start-
ing treatment (Figure 2). We believe that present case is
very rare. Our study also suggested that thyroid scintigraphy
is very useful to diagnose GD patients with the absence of
characteristic symptoms, TRAb and TSAb.
Thyroid autoantibody-negative GD is extremely rare.
We experienced a patient with GD who did not show
characteristic symptoms except for psychiatric symp-
toms, and also showed negativity for both TRAb1 and
TSAb. Thyroid scintigraphy was useful to diagnose such
a patient.Consent
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